Alogliptin (codenamed SYR-322 trade name Nesina) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class developed by Syrrx a company which was acquired by Takeda Pharmaceutical Company in 2005. Like other medications for the treatment of Type 2 diabetes alogliptin does not decrease the risk of heart attack and stroke.
This page contains content from the copyrighted Wikipedia article "Alogliptin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
